QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:PDSB

PDS Biotechnology Stock Forecast, Price & News

$11.66
-0.09 (-0.77 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.55
$11.99
50-Day Range
$9.59
$17.08
52-Week Range
$1.87
$17.85
Volume
154,166 shs
Average Volume
1.24 million shs
Market Capitalization
$331.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.63
30 days | 90 days | 365 days | Advanced Chart
Receive PDSB News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.


PDS Biotechnology logo

About PDS Biotechnology

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PDSB
Employees
15
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.22 per share

Profitability

Net Income
$-14.85 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$331.42 million
Next Earnings Date
11/10/2021 (Confirmed)
Fiscal Year End
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

712th out of 1,372 stocks

Pharmaceutical Preparations Industry

339th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












PDS Biotechnology (NASDAQ:PDSB) Frequently Asked Questions

Is PDS Biotechnology a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PDS Biotechnology stock.
View analyst ratings for PDS Biotechnology
or view top-rated stocks.

What stocks does MarketBeat like better than PDS Biotechnology?

Wall Street analysts have given PDS Biotechnology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PDS Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PDS Biotechnology?

PDS Biotechnology saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 812,700 shares, an increase of 66.2% from the September 30th total of 489,100 shares. Based on an average daily volume of 470,900 shares, the short-interest ratio is currently 1.7 days.
View PDS Biotechnology's Short Interest
.

When is PDS Biotechnology's next earnings date?

PDS Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for PDS Biotechnology
.

How can I listen to PDS Biotechnology's earnings call?

PDS Biotechnology will be holding an earnings conference call on Wednesday, November 10th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) issued its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.14.
View PDS Biotechnology's earnings history
.

How has PDS Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

PDS Biotechnology's stock was trading at $0.9201 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PDSB shares have increased by 1,167.3% and is now trading at $11.66.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PDSB?

6 Wall Street analysts have issued 1 year target prices for PDS Biotechnology's shares. Their forecasts range from $11.00 to $25.00. On average, they expect PDS Biotechnology's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 67.2% from the stock's current price.
View analysts' price targets for PDS Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are PDS Biotechnology's key executives?

PDS Biotechnology's management team includes the following people:
  • Frank K. Bedu-Addo, President, Chief Executive Officer & Director
  • Seth L. van Voorhees, Chief Financial & Accounting Officer
  • Gregory L. Conn, Chief Medical Officer
  • Joe J. Dervan, Vice President-Research & Development
  • Janetta Trochimiuk, Controller

What other stocks do shareholders of PDS Biotechnology own?

What is PDS Biotechnology's stock symbol?

PDS Biotechnology trades on the NASDAQ under the ticker symbol "PDSB."

Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Andesa Financial Management Inc. (0.06%) and Total Clarity Wealth Management Inc. (0.06%). Company insiders that own PDS Biotechnology stock include Delyle W Bloomquist, Steve C Glover and Voorhees Seth Van.
View institutional ownership trends for PDS Biotechnology
.

Which institutional investors are selling PDS Biotechnology stock?

PDSB stock was sold by a variety of institutional investors in the last quarter, including Andesa Financial Management Inc..
View insider buying and selling activity for PDS Biotechnology
or view top insider-selling stocks.

Which institutional investors are buying PDS Biotechnology stock?

PDSB stock was bought by a variety of institutional investors in the last quarter, including Total Clarity Wealth Management Inc.. Company insiders that have bought PDS Biotechnology stock in the last two years include Delyle W Bloomquist, Steve C Glover, and Voorhees Seth Van.
View insider buying and selling activity for PDS Biotechnology
or or view top insider-buying stocks.

How do I buy shares of PDS Biotechnology?

Shares of PDSB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PDS Biotechnology's stock price today?

One share of PDSB stock can currently be purchased for approximately $11.66.

How much money does PDS Biotechnology make?

PDS Biotechnology has a market capitalization of $331.42 million. The company earns $-14.85 million in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does PDS Biotechnology have?

PDS Biotechnology employs 15 workers across the globe.

What is PDS Biotechnology's official website?

The official website for PDS Biotechnology is www.pdsbiotech.com.

Where are PDS Biotechnology's headquarters?

PDS Biotechnology is headquartered at 25B Vreeland Road, Florham Park NJ, 07932.

How can I contact PDS Biotechnology?

PDS Biotechnology's mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The company can be reached via phone at (800) 208-3343 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.